Literature DB >> 25632932

MicroRNAs and benign biliary tract diseases.

Sergio A Gradilone1, Steven P O'Hara1, Tetyana V Masyuk1, Maria Jose Lorenzo Pisarello1, Nicholas F LaRusso1.   

Abstract

Cholangiocytes, the epithelial cells lining the biliary tree, represent only a small portion of the total liver cell population (3-5%), but they are responsible for the secretion of up to 40% of total daily bile volume. In addition, cholangiocytes are the target of a diverse group of liver diseases affecting the biliary tract, the cholangiopathies; for most of these conditions, the pathological mechanisms are unclear. MicroRNAs (miRNAs) are small, noncoding RNAs that posttranscriptionally regulate gene expression. Thus, it is not surprising that altered miRNA profiles underlie the dysregulation of several proteins involved in the pathobiology of the cholangiopathies, as well as showing promise as diagnostic and prognostic tools. Here the authors review recent work relevant to the role of miRNAs in the etiopathogenesis of several of the cholangiopathies (i.e., fibroinflammatory cholangiopathies and polycystic liver diseases), discuss their value as prognostic and diagnostic tools, and provide suggestions for further research. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25632932      PMCID: PMC4413449          DOI: 10.1055/s-0034-1397346

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  97 in total

Review 1.  Polycystic liver diseases: congenital disorders of cholangiocyte signaling.

Authors:  Mario Strazzabosco; Stefan Somlo
Journal:  Gastroenterology       Date:  2011-04-22       Impact factor: 22.682

2.  Multiple TLRs are expressed in human cholangiocytes and mediate host epithelial defense responses to Cryptosporidium parvum via activation of NF-kappaB.

Authors:  Xian-Ming Chen; Steven P O'Hara; Jeremy B Nelson; Patrick L Splinter; Aaron J Small; Pamela S Tietz; Andrew H Limper; Nicholas F LaRusso
Journal:  J Immunol       Date:  2005-12-01       Impact factor: 5.422

3.  Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation.

Authors:  K M Boberg; A Bergquist; S Mitchell; A Pares; F Rosina; U Broomé; R Chapman; O Fausa; T Egeland; G Rocca; E Schrumpf
Journal:  Scand J Gastroenterol       Date:  2002-10       Impact factor: 2.423

4.  Progressive renal distortion by multiple cysts in transgenic mice expressing artificial microRNAs against Pkd1.

Authors:  Ellian Wang; Hsiu-Mei Hsieh-Li; Yuan-Yow Chiou; Yi-Lin Chien; Hua-Hui Ho; Hsian-Jean Chin; Chi-Kuang Leo Wang; San-Chi Liang; Si-Tse Jiang
Journal:  J Pathol       Date:  2010-11       Impact factor: 7.996

5.  NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses.

Authors:  Konstantin D Taganov; Mark P Boldin; Kuang-Jung Chang; David Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-02       Impact factor: 11.205

Review 6.  Systematic review: the pathophysiology and management of polycystic liver disease.

Authors:  F Temmerman; L Missiaen; B Bammens; W Laleman; D Cassiman; C Verslype; J van Pelt; F Nevens
Journal:  Aliment Pharmacol Ther       Date:  2011-07-26       Impact factor: 8.171

Review 7.  Ludwig symposium on biliary disorders--part I. Pathogenesis of ductal plate abnormalities.

Authors:  V J Desmet
Journal:  Mayo Clin Proc       Date:  1998-01       Impact factor: 7.616

Review 8.  Autosomal dominant polycystic kidney disease: genetics, mutations and microRNAs.

Authors:  Ying-Cai Tan; Jon Blumenfeld; Hanna Rennert
Journal:  Biochim Biophys Acta       Date:  2011-03-17

9.  The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma.

Authors:  Lei Chen; He-Xin Yan; Wen Yang; Liang Hu; Le-Xin Yu; Qiong Liu; Liang Li; Dan-Dan Huang; Jin Ding; Feng Shen; Wei-Ping Zhou; Meng-Chao Wu; Hong-Yang Wang
Journal:  J Hepatol       Date:  2008-11-21       Impact factor: 25.083

10.  MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease.

Authors:  Seung-Ok Lee; Tatyana Masyuk; Patrick Splinter; Jesús M Banales; Anatoliy Masyuk; Angela Stroope; Nicholas Larusso
Journal:  J Clin Invest       Date:  2008-10-23       Impact factor: 14.808

View more
  12 in total

Review 1.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

Review 2.  Current challenges to underpinning the genetic basis for cholangiocarcinoma.

Authors:  Antonio Cigliano; Xin Chen; Diego F Calvisi
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2021-04-23       Impact factor: 3.869

Review 3.  Long noncoding RNAs-a new dimension in the molecular architecture of the bile acid/FXR pathway.

Authors:  Yonghe Ma; Jamie Harris; Ping Li; Haiming Cao
Journal:  Mol Cell Endocrinol       Date:  2021-02-01       Impact factor: 4.102

4.  Use of Serum MicroRNAs as Biomarker for Hepatobiliary Diseases in Dogs.

Authors:  K Dirksen; T Verzijl; G C Grinwis; R P Favier; L C Penning; I A Burgener; L J van der Laan; H Fieten; B Spee
Journal:  J Vet Intern Med       Date:  2016-11-11       Impact factor: 3.333

Review 5.  NcRNAs and Cholangiocarcinoma.

Authors:  Zheng Wangyang; Ji Daolin; Xu Yi; Li Zhenglong; Huang Lining; Cui Yunfu; Jiang Xingming
Journal:  J Cancer       Date:  2018-01-01       Impact factor: 4.207

6.  Serum levels of miR-29, miR-122, miR-155 and miR-192 are elevated in patients with cholangiocarcinoma.

Authors:  Sven H Loosen; Georg Lurje; Georg Wiltberger; Mihael Vucur; Alexander Koch; Jakob N Kather; Pia Paffenholz; Frank Tacke; Florian T Ulmer; Christian Trautwein; Tom Luedde; Ulf P Neumann; Christoph Roderburg
Journal:  PLoS One       Date:  2019-01-17       Impact factor: 3.240

7.  H19 potentiates let-7 family expression through reducing PTBP1 binding to their precursors in cholestasis.

Authors:  Li Zhang; Zhihong Yang; Wendong Huang; Jianguo Wu
Journal:  Cell Death Dis       Date:  2019-02-18       Impact factor: 8.469

Review 8.  MicroRNAs in the Cholangiopathies: Pathogenesis, Diagnosis, and Treatment.

Authors:  Maria Jose Lorenzo Pisarello; Lorena Loarca; Tommy Ivanics; Leslie Morton; Nicholas LaRusso
Journal:  J Clin Med       Date:  2015-08-26       Impact factor: 4.241

Review 9.  The changing faces of cholangitis.

Authors:  Sum P Lee; Joseph R Roberts; Rahul Kuver
Journal:  F1000Res       Date:  2016-06-17

10.  Downregulation of microRNA-145 may contribute to liver fibrosis in biliary atresia by targeting ADD3.

Authors:  Yongqin Ye; Zhihan Li; Qi Feng; Zimin Chen; Zhouguang Wu; Jianyao Wang; Xiaoshuo Ye; Dahao Zhang; Lei Liu; Wei Gao; Lihui Zhang; Bin Wang
Journal:  PLoS One       Date:  2017-09-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.